Loading stock data…
SDGR
$12.39+0.43 (+3.60%)
Market ClosedLast close May 1
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Schrödinger, Inc. in the Healthcare sector is trading at $12.39. The stock is currently near its 52-week low of $10.95, remaining 26.5% below its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why SDGR maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$12.39
Potential Upside
5%
Whystock Fair Value$13.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Af...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$911.74M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.81%
Volume
Today's trading volume
1.00M
Recent News
What’s Schrodinger Inc (SDGR) Working Out with Anthropic?
Schrodinger Inc (NASDAQ:SDGR) is among the best medical AI stocks to buy now. Schrodinger Inc (NASDAQ:SDGR)’s management presented at the 2026 KeyBanc Capital Markets Healthcare Forum on March 17. The presentation covered the company’s strategic direction, with the management discussing a shift to hosted software contracts and leveraging AI to expand the user base. The […]
How The Schrödinger (SDGR) Narrative Is Shifting With Hosted Software And Lower Price Targets
Schrödinger’s fair value estimate has been trimmed from US$23.50 to US$21.38, a move that lines up with a wider round of price target cuts across the Street. Analysts tying these changes to the growing mix of hosted software point to short term noise in reported revenue and investor perception, even as some maintain Buy ratings and focus on underlying usage trends. As you read on, you will see how to track these shifting targets and what they may signal for the evolving Schrödinger...
Schrodinger Conference: SDGR Targets Hosted Shift, Platform Adoption, EBITDA Profitability in 3 Years
Schrodinger (NASDAQ:SDGR) executives outlined a strategy focused on expanding adoption of its computational chemistry platform, accelerating a shift to hosted software delivery, and partnering out internal clinical-stage assets during a virtual fireside chat at an annual healthcare forum. Platform
How The Schrödinger (SDGR) Investment Story Is Evolving With Hosted Software And Reset Targets
Schrödinger’s updated analyst framework trims its fair value estimate from US$27.30 to US$23.50, roughly a 14% reset to the price target. This shift aligns with recent research that balances long term optimism about the business model with more caution around near term execution, valuation, and the move toward hosted software. As you read on, you will see how these changing targets fit into the broader analyst narrative and what to watch as it evolves. Stay updated as the Fair Value for...
Schrödinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth
Schrodinger Inc. (NASDAQ:SDGR) is one of the best cancer stocks to invest in now. On February 25, Schrodinger Inc. (NASDAQ:SDGR) delivered solid fourth-quarter and full-year 2025 results characterized by robust revenue growth. The company also announced it is accelerating its transition to a licensing model to establish a more predictable, higher-visibility revenue stream. Full-year revenue […]